GlassScriptPhysician profile
Sinnamon Waugh
NPI 1184048233
$13,976.28
in general payments reported to CMS, 2019-2025
53 companies · $3,306 in 2025
The $3,306 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,122 · 2022: $2,596 · 2023: $2,690 · 2024: $3,263 · 2025: $3,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,232 · Education: $26.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,231.86 |
| Education | $26.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,739.46 | 2021-2025 | |
| Ucb, INC. | $1,506.25 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Neurelis, INC. | $1,070.47 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $968.21 | 2022-2025 | |
| Lundbeck LLC | $921.78 | 2021-2025 | Vyepti |
| Sk Life Science, INC. | $758.56 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $734.33 | 2021-2025 | Qelbree, Qelbree |
| Eisai INC. | $682.80 | 2021-2025 | |
| Lilly USA, LLC | $538.07 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Pfizer INC. | $500.37 | 2023-2025 | |
| Corium, LLC | $463.88 | 2022-2025 | Azstarys |
| Tris Pharma INC | $346.97 | 2021-2025 | Dyanavel Xr, Onyda Xr |
| Amneal Pharmaceuticals LLC | $332.48 | 2021-2025 | Rytary, Lyvispah, Crexont |
| Catalyst Pharmaceuticals, INC. | $323.69 | 2023-2025 | Fycompa |
| Biohaven Pharmaceutical Holding Company LTD. | $294.32 | 2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sinnamon Waugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.